Possibilities of use of metformin for correction of endothelial dysfunction and adaptation reserves of an organism in patients with metabolic syndrome

Cover Page

Cite item

Abstract

Aim. To study possibilities of pharmaceutical correction of clinical laboratory parameters, of endothelial dysfunction and non-specific adaptation reserves in patients with metabolic syndrome (MS) through use of metformin.

Materials and Methods. The three-month program involved 53 patients with MS rando-mized to two comparable groups. Patients of the control group were kept on individual low-calorie diet and practiced graduated exercises. Patients of the studied group, besides the mentioned program of modification of the lifestyle, took metformin. In all participants, anthropometric and clinical laboratory parameters were twice evaluated, total body composition, condition of vascular endothelium and non-specific adaptation reserves of an organism were analyzed. The extent of endothelial dysfunction was evaluated by the level of endothelin-1 and by parameters of photoplethysmographic examination, non-specific adaptation reserves – by the method of analysis of the cardiac rhythm variability.

Results. Metformin in complex with dietary therapy and physical exercises proved to be a safe medical drug for correction of components of MS and of endothelial dysfunction. Use of metformin in patients with MS in combination with dietary therapy and graduated physical exercises as compared to use of the program of modification of the lifestyle alone, leads to reduction in the body mass, waist circumference (in women) and of the total fat mass. Introduction of metformin into the program of complex therapy of patients with MS, provides more evident correction of the parameters of carbohydrate metabolism, reduction of endothelin-1 and stiffness index of the aortic wall, enhancement of parasympathetic regulation, than modification of the lifestyle alone.

Conclusion. Use of metformin in the complex therapy of metabolic syndrome in comparison with the program of modification of the lifestyle, promotes a more significant reduction of the clinical laboratory parameters, of endothelial dysfunction and improves non-specific adaptation reserves of an organism.

About the authors

Aleksej A. Nizov

Ryazan State Medical University

Email: katya.suchkova.1990@mail.ru
ORCID iD: 0000-0001-7531-9102
SPIN-code: 2939-8193
ResearcherId: M-7081-2018

MD, PhD, Professor of the Department of Internal Diseases

Russian Federation, Ryazan

Ekaterina I. Suchkova

Ryazan State Medical University

Author for correspondence.
Email: katya.suchkova.1990@mail.ru
ORCID iD: 0000-0002-7997-0338
SPIN-code: 7506-6232
ResearcherId: G-7491-2019

Assistant of the Department of Internal Diseases

 
Russian Federation, Ryazan

Aleksej I. Grivenko

Ryazan State Medical University

Email: katya.suchkova.1990@mail.ru
ORCID iD: 0000-0002-6882-7501
SPIN-code: 3082-7017

Assistant of the Department of Internal Di-seases

Russian Federation, Ryazan

Larisa V. Nikiforova

Ryazan State Medical University

Email: katya.suchkova.1990@mail.ru
ORCID iD: 0000-0003-4369-0729
SPIN-code: 8735-8565

Senior Researcher of the Central Research Laboratory

Russian Federation, Ryazan

References

  1. Experts’ consensus on the interdisciplinary approach towards the management, diagnostics, and treatment of patients with metabolic syndrome. Cardiovascular Therapy and Prevention. 2013; 12(6):41-82. (In Russ).
  2. Mamedov MN; Oganov RG, editor. Metaboliches-kiy sindrom v Rossii: rasprostranennost’, klinicheskiye osobennosti i lecheniye. Moscow; 2011. (In Russ).
  3. Filatova TE, Nizov AA, Davydov VV. Experience of treatment of male hypertension with obesity, fasting hyperglycemia and deficiency of vitamin D. I.P. Pavlov Russian Medical Biological Herald. 2017;25(1):69-75. (In Russ). doi: 10.23888/PAV-LOVJ2017169-75
  4. Yakushin SS, Filippov EV. The main directions of the primary prevention of cardiovascular disease. Eruditio Juvenium. 2014;(4):55-67. (In Russ).
  5. Dashkevich OV, Nizov AA, Lapkin MM, et al. Metabolic syndrome in the practice of the therapist city polyclinic: experience of dietary therapy jam of laminaria, enriched with chromium, and metformin. I.P. Pavlov Russian Medical Biological Herald. 2013;(2):88-92. (In Russ).
  6. Esler M, Rumantir M, Wiesner G, et al. Sympathetic Nervous System and Insulin Resistance: From Obesity to Diabetes. American Journal of Hypertension. 2001;14(S7):304s-9s. doi: 10.1016/s0895-7061 (01)02236-1
  7. Martynov AI, Avetyak NG, Akatova EV, et al. Endothelial dysfunction and methods for its diagnostics. Russian Journal of Cardiology. 2005;4(54):94-8. (In Russ).
  8. Golivets TP, Dubonosova DG, Osipova OA, et al. The effects of endothelin 1 in the development and progression of metabolic syndrome and socially significant non-communicable diseases (review of literature). Scientific Bulletins of Belgorod State University. Series: Medicine. Pharmacia. 2017;19 (268):14-19. (In Russ).
  9. Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovascular Research. 2007;76(1):8-18. doi:10. 1016/j.cardiores.2007.06.004
  10. Verma S, Yao L, Stewart DJ, et al. Endothelin antagonism uncovers insulin-mediated vasorelaxation in vitro and in vivo. Hypertension. 2001;37(2)328-33. doi: 10.1161/01.hyp.37.2.328
  11. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009;120(13):1266-86. doi: 10.1161/CIR-CULATIONAHA.108.835223
  12. Eriksson L, Nyström T. Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis. Cardiovascular Diabetology. 2014;13(1):152. doi: 10.1186/s12933-014-0152-5
  13. Zepeda R, Castillo R, Rodrigo R, et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic & Clinical Pharmacology & Toxicology. 2012;111(5):309-16. doi:10.1111/ j.1742-7843.2012.00911.x
  14. Romantsova TI, Dzhavakhishvili TSh, Roik OV. Effects of metformin on body weight in patients with type 2 diabetes mellitus, receiving insulin analogue treatment. Diabetes Mellitus. 2013;(1):48-51. doi: 10.14341/2072-0351-3596
  15. Madiraju AK, Qiu Y, Perry RJ, et al. Author Correction: Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nature Medicine. 2019;25(3):526-8. doi: 10.1038/s41591-018-0220-6
  16. Luo F, Das A, Chen J, et al. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovascular Diabetology. 2019;18(1):54. doi: 10.1186/s12933-019-0860-y
  17. Vitale C, Mercuro G, Cornoldi A, et al. Metformin improves endothelial function in patients with me-tabolic syndrome. Journal of Internal Medicine. 2005; 258(3):250-6. doi: 10.1111/j.1365-2796.2005. 01531.x
  18. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology. 2005;152(5):749-56. doi: 10.1530/eje.1.0191

Copyright (c) 2020 Nizov A.A., Suchkova E.I., Grivenko A.I., Nikiforova L.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies